Magnetresonanztomographie bei Patienten mit Morbus Parkinson und Parkinson-Plus-Syndromen

Hierholzer, J.; Schrag, Anette; Cordes, Michael; Sander, B.; Schelosky, Ludwig; Harisch, Cordula; Venz, Stephan; Keske, U.; Mäurer, J.; Poewe, W.; Félix, R.

doi:10.1055/s-2007-1015712

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Infratentorielle atrophische Veränderun-gen werden in der Literatur [6,14] über-wiegend als typische Zeichen einer zerebellären Verlaufsform der MSA beschrieben.Yagishita und Oda [22] fanden jedoch ebenfalls eine Kleinhirn-und Ponsatrophie sowie Signalveränderungen in der Brücke bei ihren Patienten mit MSA-P.Die Ergebnisse unserer Untersuchung,insbesondere die Häufigkeit einer Kleinhirnatrophie sowohl bei Patienten mit MSA-P als auch mit PSP,lassen berechtigten Zweifel an der bisher angenommenen hohen Spezifität dieser Veränderungen für die hier nicht untersuchte Gruppe der MSA-C-Patienten in der Unterscheidung zur striatonigralen Form der MSA aufkommen. Korrelationsuntersuchungen zwischen klinischer Beeinträchtigung und den gefundenen MR-tomographischen Veränderungen wurden im Rahmen dieser Studie nicht durchgeführt.…”

Section: Multisystematrophie Vom Striatonigralen Typunclassified

Differenzierung atypischer Parkinson-Syndrome und ihre Abgrenzung vom idiopathischen Parkinson-Syndrom mit Hilfe der Routine-Magnetresonanztomographie

Csóti¹,

Warmuth‐Metz

Solymosi

et al. 2004

Nervenarzt

View full text Add to dashboard Cite

Atrophy of frontal lobe, midbrain, pons, and cerebellum was studied in 16 patients with progressive supranuclear palsy (PSP), 14 with multiple system atrophy of striatonigral type (MSA-P), 20 with idiopathic Parkinson's disease (IPS), and 12 age-matched healthy controls using axial T2-weighted MR images (1.5 Teslar). With <16 mm, the PSP group showed significantly lower anteroposterior midbrain diameters than the IPS, MSA-P, and control groups. We conclude that measurement of the anteroposterior diameter of the midbrain with axial T2-weighted MRI is a useful feature and should be incorporated into the diagnostic criteria for PSP. In addition to the typical slit hyperintensity in margin of putamen and decreased signal intensity in dorsolateral putamen, we found cerebellar atrophy in 64% of patients with MSA-P. Before now, this was considered a typical sign of multiple system atrophy of cerebellar type (MSA-C). The use of this feature in the differential diagnosis of both types of multiple system atrophy is debatable.

show abstract

Section: Multisystematrophie Vom Striatonigralen Typunclassified

Differenzierung atypischer Parkinson-Syndrome und ihre Abgrenzung vom idiopathischen Parkinson-Syndrom mit Hilfe der Routine-Magnetresonanztomographie

Csóti¹,

Warmuth‐Metz

Solymosi

et al. 2004

Nervenarzt

View full text Add to dashboard Cite

show abstract

“…These receptors co‐localize with striatal dopamine type 2 (D 2 ) receptors, in the form of heterodimers, and the two receptors are functionally linked . This functional link makes the A 2A receptor an alternative therapeutic target, to the D 2 receptor, for the treatment of movement disorders, such as Parkinson′s and Huntingdon′s disease (PD and HD), as well as ischemic brain damage and epilepsy . Furthermore, dysregulation of A 2A receptors has been linked to psychiatric disorders such as schizophrenia, attention deficit hyperactivity disorder, mood disorder, depression, and addiction …”

Section: Introductionmentioning

confidence: 99%

Synthesis and in vivo Evaluation of Fluorine‐18 and Iodine‐123 Pyrazolo[4,3‐e]‐1,2,4‐triazolo[1,5‐c]pyrimidine Derivatives as PET and SPECT Radiotracers for Mapping A_2A Receptors

et al. 2016

View full text Add to dashboard Cite

Imaging agents that target adenosine type 2A (A2A ) receptors play an important role in evaluating new pharmaceuticals targeting these receptors, such as those currently being developed for the treatment of movement disorders like Parkinson's disease. They are also useful for monitoring progression and treatment efficacy by providing a noninvasive tool to map changes in A2A receptor density and function in neurodegenerative diseases. We previously described the successful evaluation of two A2A -specific radiotracers in both nonhuman primates and in subsequent human clinical trials: [(123) I]MNI-420 and [(18) F]MNI-444. Herein we describe the development of both of these radiotracers by selection from a series of A2A ligands, based on the pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine core of preladenant. Each of this series of 16 ligands was found to bind to recombinant human A2A receptor in the low nanomolar range, and of these 16, six were radiolabeled with either fluorine-18 or iodine-123 and evaluated in nonhuman primates. These initial in vivo results resulted in the identification of 7-(2-(4-(4-(2-[(18) F]fluoroethoxy)phenyl)piperazin-1-yl)ethyl)-2-(furan-2-yl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine ([(18) F]MNI-444) and 7-(2-(4-(2-fluoro-4-[(123) I]iodophenyl)piperazin-1-yl)ethyl)-2-(furan-2-yl)-7H-imidazo[1,2-c]pyrazolo[4,3-e]pyrimidin-5-amine ([(123) I]MNI-420) as PET and SPECT radiopharmaceuticals for mapping A2A receptors in brain.

show abstract

Magnetresonanztomographie bei Patienten mit Morbus Parkinson und Parkinson-Plus-Syndromen

Abstract: MRI enables us to define characteristic morphological changes of the brain in patients with extrapyramidal movement disorders. Early recognition of these findings avoids misdiagnoses in patients who are difficult to diagnose.

Cited by 2 publications

References 0 publications

Differenzierung atypischer Parkinson-Syndrome und ihre Abgrenzung vom idiopathischen Parkinson-Syndrom mit Hilfe der Routine-Magnetresonanztomographie

Differenzierung atypischer Parkinson-Syndrome und ihre Abgrenzung vom idiopathischen Parkinson-Syndrom mit Hilfe der Routine-Magnetresonanztomographie

Synthesis and in vivo Evaluation of Fluorine‐18 and Iodine‐123 Pyrazolo[4,3‐e]‐1,2,4‐triazolo[1,5‐c]pyrimidine Derivatives as PET and SPECT Radiotracers for Mapping A_2A Receptors

Contact Info

Product

Resources

About

Magnetresonanztomographie bei Patienten mit Morbus Parkinson und Parkinson-Plus-Syndromen

Abstract: MRI enables us to define characteristic morphological changes of the brain in patients with extrapyramidal movement disorders. Early recognition of these findings avoids misdiagnoses in patients who are difficult to diagnose.

Cited by 2 publications

References 0 publications

Differenzierung atypischer Parkinson-Syndrome und ihre Abgrenzung vom idiopathischen Parkinson-Syndrom mit Hilfe der Routine-Magnetresonanztomographie

Differenzierung atypischer Parkinson-Syndrome und ihre Abgrenzung vom idiopathischen Parkinson-Syndrom mit Hilfe der Routine-Magnetresonanztomographie

Synthesis and in vivo Evaluation of Fluorine‐18 and Iodine‐123 Pyrazolo[4,3‐e]‐1,2,4‐triazolo[1,5‐c]pyrimidine Derivatives as PET and SPECT Radiotracers for Mapping A2A Receptors

Contact Info

Product

Resources

About

Synthesis and in vivo Evaluation of Fluorine‐18 and Iodine‐123 Pyrazolo[4,3‐e]‐1,2,4‐triazolo[1,5‐c]pyrimidine Derivatives as PET and SPECT Radiotracers for Mapping A_2A Receptors